Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period

This study has been completed.
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00575588
First received: December 14, 2007
Last updated: March 20, 2012
Last verified: March 2012
  Purpose

Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.


Condition Intervention Phase
Type 2 Diabetes
Drug: Metformin
Drug: Sulphonylurea
Drug: Saxagliptin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 52-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Hemoglobin A1c (HbA1c) Change From Baseline to Week 52 [ Time Frame: Baseline to 52 Weeks ] [ Designated as safety issue: No ]
    Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 52 (Per Protocol Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 52 value minus the baseline value.


Secondary Outcome Measures:
  • Proportion of Participants Reporting at Least One Episode of Any Hypoglycaemic Event Over 52 Weeks [ Time Frame: From Baseline to Week 52 ] [ Designated as safety issue: Yes ]
    Proportion of participants reporting at least one episode of any hypoglycaemic event for saxagliptin added on to metformin versus glipizide added on to metformin over 52 weeks (Safety Analysis Set)

  • Body Weight Change From Baseline to Week 52 [ Time Frame: Baseline, Week 52 (Last Observation Carried Forward) ] [ Designated as safety issue: Yes ]
    Adjusted mean change from baseline in Body Weight achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 52 (Safety Analysis Set). Body Weight is a continuous measure, the change from baseline for each participant is calculated as the Week 52 (LOCF) value minus the baseline value.

  • Mean Slope of the Regressions of Change From Week 24 to Week 52 in HbA1c [ Time Frame: Week 24 to Week 52 ] [ Designated as safety issue: No ]
    Mean slopes of regression of change from Week 24 to Week 52 in HbA1c for saxagliptin added on to metformin versus glipizide added on to metformin (Per Protocol Analysis Set) achieved by fitting a mixed model with subject specific slopes for the time effect (weeks on randomized treatment was utilized). This analysis gives an assessment of the durability of the HbA1c effect.


Enrollment: 891
Study Start Date: December 2007
Study Completion Date: August 2010
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Saxagliptin Drug: Metformin
open-label metformin
Drug: Saxagliptin
Saxagliptin 5 mg tablets
Other Name: Onglyza
Experimental: Glipizide Drug: Metformin
open-label metformin
Drug: Sulphonylurea
Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with type 2 diabetes,
  • Treatment with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks prior to Visit 1,
  • HbA1c >6.5% and ≤10.0%

Exclusion Criteria:

  • Type 1 diabetes,
  • history of diabetic ketoacidosis or hyperosmolar non-ketonic coma,
  • Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00575588

  Hide Study Locations
Locations
Finland
Research Site
Hanko, Finland
Research Site
Helsinki, Finland
Research Site
Kuopio, Finland
Research Site
Kuusankoski, Finland
Research Site
Mikkeli, Finland
Research Site
Oulu, Finland
Research Site
Tampere, Finland
Germany
Research Site
Aschaffenburg, Germany
Research Site
Berlin, Germany
Research Site
Dortmund, Germany
Research Site
Frankfurt, Germany
Research Site
Hamburg, Germany
Research Site
Hannover, Germany
Research Site
Mainz, Germany
Research Site
Mannheim, Germany
Research Site
Mulheim, Germany
Research Site
Pirna, Germany
Research Site
Ratzeburg, Germany
Research Site
Reinfeld, Germany
Research Site
Rhaunen, Germany
Research Site
Schmiedeberg, Germany
Research Site
Tubingen, Germany
Research Site
Wahlstedt, Germany
Research Site
Weinheim, Germany
Hungary
Research Site
Balatonfured, Hungary
Research Site
Bekescsaba, Hungary
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Gyula, Hungary
Research Site
Kalocsa, Hungary
Research Site
Kaposvar, Hungary
Research Site
Kecskemet, Hungary
Research Site
Miskolc, Hungary
Research Site
Mosonmagyarovar, Hungary
Research Site
Nyiregyhaza, Hungary
Research Site
Szekesfehervar, Hungary
India
Research Site
Bangalore, Karnataka, India
Research Site
Indore, Madhya Pradesh, India
Research Site
Mumbai, Mashatra, India
Research Site
Jaipur, Rajasthan, India
Korea, Republic of
Research Site
Guri, Gyeonggi-do, Korea, Republic of
Research Site
Seongnam, Gyeonggi-do, Korea, Republic of
Research Site
Wonju, Kangwon-do, Korea, Republic of
Research Site
Incheon, Korea, Republic of
Research Site
Seoul, Korea, Republic of
Research Site
Uijeongbu-si, Korea, Republic of
Netherlands
Research Site
Beek En Donk, Netherlands
Research Site
Den Bosch, Netherlands
Research Site
Den Haag, Netherlands
Research Site
Deurne, Netherlands
Research Site
Dordrecht, Netherlands
Research Site
Losser, Netherlands
Research Site
Nijverdal, Netherlands
Research Site
Rijswijk, Netherlands
Research Site
Roelofarendsveen, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Volendam, Netherlands
Norway
Research Site
Bergen, Norway
Research Site
Elverum, Norway
Research Site
Flatasen, Norway
Research Site
Hamar, Norway
Research Site
Honefoss, Norway
Research Site
Inderoy, Norway
Research Site
Oslo, Norway
Research Site
Radal, Norway
Research Site
Skedsmokorset, Norway
Research Site
Sogndal, Norway
Research Site
Spikkestad, Norway
Research Site
Trollasen, Norway
Russian Federation
Research Site
Kazan, Russian Federation
Research Site
Moscow, Russian Federation
Research Site
Nizhnii Novgorod, Russian Federation
Research Site
St. Petersburg, Russian Federation
Research Site
Yaroslavl, Russian Federation
Slovakia
Research Site
Dolny Kubin, Slovakia
Research Site
Kosice - Tahanovce, Slovakia
Research Site
Moldava Nad Bodvou, Slovakia
Research Site
Ruzomberok, Slovakia
Research Site
Trnava, Slovakia
Research Site
Zilina, Slovakia
United Kingdom
Research Site
Annan, Dumfries and Galloway, United Kingdom
Research Site
Whitstable, Kent, United Kingdom
Research Site
Hamilton, Lanarkshire, United Kingdom
Research Site
Salford, Manchester, United Kingdom
Research Site
Crawley, West Sussex, United Kingdom
Research Site
Bradford-on-avon, Wiltshire, United Kingdom
Research Site
Blackpool, United Kingdom
Research Site
Coatbridge, United Kingdom
Research Site
Coventry, United Kingdom
Research Site
Glasgow, United Kingdom
Research Site
Motherwell, United Kingdom
Research Site
Newcastle, United Kingdom
Research Site
Sheffield, United Kingdom
Vietnam
Research Site
Ho Chi Minh, Vietnam
Research Site
Ho Chi Minh City, Vietnam
Sponsors and Collaborators
AstraZeneca
Bristol-Myers Squibb
Investigators
Principal Investigator: Burkhard Goke University of Munich, Germany
Study Director: Peter Ohman, MD AstraZeneca
Study Chair: Deborah Price, MSc AstraZeneca
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00575588     History of Changes
Other Study ID Numbers: D1680C00001, EudraCT number 2007-003998-55
Study First Received: December 14, 2007
Results First Received: August 10, 2010
Last Updated: March 20, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by AstraZeneca:
DPP-4 Inhibitors
HbA1c
incretins

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Metformin
Saxagliptin
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Hypoglycemic Agents
Incretins
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors

ClinicalTrials.gov processed this record on November 25, 2014